entecavir has been researched along with Pneumonia--Viral* in 2 studies
2 other study(ies) available for entecavir and Pneumonia--Viral
| Article | Year |
|---|---|
A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Cidofovir; Coronavirus Infections; COVID-19; Dideoxynucleosides; Ganciclovir; Guanine; Nucleotides; Pandemics; Pneumonia, Viral; Prodrugs; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Stavudine; Valganciclovir | 2020 |
Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents.
Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose to find effective and low-toxic drugs to mitigate CSS, entecavir and imipenem were identified to reduce TNF-α using a LPS-induced macrophage model from the anti-infective drug library. Entecavir and imipenem efficiently suppressed the release of inflammatory cytokines by partly intervention of NF-κB activity. The acute lung injury was also alleviated and the survival time was prolonged in mice. In addition, entecavir and imipenem inhibited the release of TNF-α and IL-10 in human peripheral blood mononuclear cells (hPBMCs). Collectively, we proposed that entecavir and imipenem might be candidates for the treatment of CSS. Topics: Acute Lung Injury; Animals; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Drug Repositioning; Guanine; Humans; Imipenem; Interleukin-10; Leukocytes, Mononuclear; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Pandemics; Pneumonia, Viral; Tumor Necrosis Factor-alpha | 2020 |